Deccan Health Care Ltd (542248)

Deccan Health Care reported a consolidated revenue of ₹22.07 Cr for Q1 FY27, representing a marginal 0.3% decline YoY but a 5.2% growth over the preceding March quarter. Consolidated Net Profit stood at ₹0.29 Cr, up from ₹0.24 Cr in Q1 FY26, though it declined sequentially from ₹0.33 Cr in Q4 FY26. The company continues to operate with thin net margins of approximately 1.3%. Notably, finance costs surged to ₹15.62 Lakhs from ₹1.71 Lakhs in the year-ago period, indicating increased debt servicing requirements.

• Consolidated Revenue from Operations stood at ₹22.07 Cr for the quarter ended June 30, 2026.
• Net Profit after tax (Consolidated) increased 22.8% YoY to ₹0.29 Cr.
• Finance costs witnessed a sharp increase to ₹15.62 Lakhs compared to ₹1.71 Lakhs in Q1 FY26.
• Cost of materials consumed spiked to ₹22.66 Cr, largely offset by a ₹7.45 Cr increase in inventory value.
• Earnings Per Share (EPS) for the quarter remained low at ₹0.12.

Deccan Health Care reported a stagnant consolidated revenue of ₹22.07 Cr for Q1 FY27, compared to ₹22.14 Cr in the same period last year. Despite the flat top-line, consolidated net profit increased by 22.8% YoY to ₹0.29 Cr, up from ₹0.24 Cr. The company continues to operate with extremely thin margins, with a consolidated PBT margin of just 1.76%. Standalone revenue showed a marginal improvement of 1.8% YoY to ₹21.86 Cr.

• Consolidated Revenue from Operations stood at ₹22.07 Cr for the quarter ended June 30, 2026
• Consolidated Net Profit increased to ₹0.29 Cr from ₹0.24 Cr in the previous year's corresponding quarter
• Cost of materials consumed rose significantly to ₹22.66 Cr (Consolidated) from ₹19.12 Cr YoY
• Inventory adjustments (Finished Goods/WIP) provided a credit of ₹7.45 Cr to offset high material costs
• Basic and Diluted EPS for the quarter improved slightly to ₹0.12 from ₹0.10 YoY

Deccan Health Care Ltd has scheduled a board meeting for August 14, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company currently operates with a small market capitalization of Rs 33 Cr and reported a TTM revenue of Rs 82 Cr. The trading window for insiders has been closed since July 01, 2026, and will remain so until 48 hours after the results are declared. This is a routine regulatory filing in compliance with SEBI (LODR) Regulations.

• Board meeting scheduled for August 14, 2026, to review Q1 FY27 results.
• Trading window for designated persons closed since July 01, 2026.
• Company reported TTM revenue of Rs 82 Cr and a PAT of Rs 2 Cr.
• Promoter holding remains relatively low at 19.46% as of June 2026.
• The company maintains a low debt-to-equity ratio of 0.04.

Deccan Health Care shareholders approved the regularization of three Independent Directors—Mr. Bhupender Singh, Ms. Manju Singh, and Ms. Pratiksha Bisht—at an EGM held on July 24, 2026. These directors, initially appointed in April 2026, will now serve a five-year term until April 2031. The move strengthens the board of this micro-cap company (Rs 31 Cr market cap) which currently operates with a low promoter holding of 19.5%. The new directors bring experience from government administration, real estate, and social services to various board committees.

• 3 Independent Directors regularized for a fixed 5-year term effective from April 25, 2026
• Bhupender Singh Kataria joins with 30 years of experience in government administration and operations
• All three newly regularized directors hold 0 shares in the company as of the appointment date
• Appointments cover key board functions including Audit, CSR, and Nomination & Remuneration committees
• Approval was finalized at an Extra-Ordinary General Meeting (EGM) held on July 24, 2026